Jazz Pharmaceuticals PLC Xywav Investor Update Transcript
Hi. Good day. This is Kathee Littrell, Head of Investor Relations at Jazz. I want to thank you all for joining for our Xywav Investor Update.
Before we begin the webcast, I will point out that we will be making forward-looking statements today including statements regarding our plans and expectations for the Xywav commercial launch in the U.S., potential Xywav's revenue opportunity and our other development plans and opportunities. Our forward-looking statements are subject to risks and uncertainties described in our quarterly report on Form 10-Q for the quarter ended June 30, 2020, and our other filings with the Securities and Exchange Commission and actual results may differ materially. We undertake no duty or obligation to update any forward-looking statements we make today. Finally, we are not confirming or updating any other guidance and actual results may differ.
I'll remind you that you can send in questions at any time during the presentation, and we will address those during the press -- after the presentations are over
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |